← HALOZYME THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $66.8m | $168.7m | $57.9m | $120.2m | $147.7m | $118.7m | $234.2m | $118.4m | $115.8m | $133.8m | |
| Prepaid Expense and Other Assets, Current | $21.2m | $13.9m | $20.7m | $33.4m | $28.3m | $40.5m | $45.0m | $48.6m | $39.0m | $64.6m | |
| Inventory, Net | $14.6m | $5.1m | $22.6m | $29.4m | $60.7m | $53.9m | $100.1m | $127.6m | $141.9m | $176.5m | |
| Assets, Current | $256.5m | $510.4m | $427.8m | $543.4m | $554.8m | $926.3m | $739.0m | $746.4m | $1.1b | $825.2m | |
| Property, Plant and Equipment, Net | $4.3m | $3.5m | $7.5m | $10.9m | $10.6m | $6.8m | $35.1m | $38.1m | $40.9m | $44.4m | |
| Goodwill | — | — | — | — | — | $0 | $409.0m | $416.8m | $416.8m | $580.4m | |
| Intangible Assets, Net (Excluding Goodwill) | — | — | — | — | — | — | $546.7m | $472.9m | $401.8m | $981.5m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $3.8m | $3.3m | $2.0m | $40.5m | $36.8m | $34.2m | $37.7m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $15.7m | $22.1m | $30.0m | $59.4m | $97.7m | $91.0m | $231.1m | — | $288.2m | $426.3m | |
| Accrued Liabilities, Current | $28.8m | $39.6m | $49.5m | $55.6m | $20.5m | $24.4m | $96.5m | $100.7m | $128.9m | $156.2m | |
| Assets | $261.5m | $519.9m | $440.2m | $565.9m | $579.9m | $1.1b | $1.8b | $1.7b | $2.1b | $2.5b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts Payable, Current | $3.6m | $7.9m | $4.1m | $6.4m | $1.9m | $1.5m | $17.7m | $11.8m | $10.2m | $20.9m | |
| Deferred Revenue, Current | $4.8m | $6.6m | $4.2m | — | — | — | — | — | — | — | |
| Deferred Revenue, Noncurrent | $39.8m | $54.3m | $5.0m | $1.2m | — | — | — | — | — | — | |
| Long-term Debt, Excluding Current Maturities | $199.2m | $125.1m | $34.9m | $383.0m | $0 | $787.3m | $1.5b | $1.5b | $1.5b | $2.1b | |
| Long-term Debt, Current Maturities | $17.4m | $77.2m | $91.5m | $19.5m | $397.2m | $89.4m | $13.3m | $0 | $0 | $0 | |
| Liabilities, Current | $54.6m | $131.3m | $149.4m | $85.6m | $421.4m | $117.1m | $130.8m | $112.5m | $139.1m | $177.1m | |
| Deferred Income Tax Liabilities, Net | — | — | — | — | — | — | — | — | $0 | $42.9m | |
| Other Liabilities, Noncurrent | $358k | $814k | $2.1m | $4.2m | $3.5m | $544k | $30.4m | $37.7m | $54.8m | $113.9m | |
| Deferred Tax Liabilities, Net | — | — | — | — | — | — | — | — | $0 | $42.9m | |
| Liabilities | — | — | — | — | — | — | — | $1.6b | $1.7b | $2.5b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $130k | $143k | $145k | $137k | $135k | $138k | $135k | $127k | $123k | $118k | |
| Retained Earnings (Accumulated Deficit) | ($585.3m) | ($522.4m) | ($531.4m) | ($603.7m) | ($474.6m) | ($58.9m) | $143.2m | $90.5m | $359.9m | $54.8m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($6k) | ($450k) | ($277k) | $240k | $22k | ($620k) | ($922k) | ($9.3m) | $3.8m | ($18.1m) | |
| Additional Paid in Capital, Common Stock | $552.7m | $731.0m | $780.5m | $695.1m | $625.5m | $256.3m | $27.4m | $2.4m | $0 | $12.0m | |
| Stockholders' Equity Attributable to Parent | ($32.5m) | $208.4m | $248.9m | $91.8m | $151.0m | $197.0m | $169.8m | $83.8m | $363.8m | $48.8m | |
| Liabilities and Equity | $261.5m | $519.9m | $440.2m | $565.9m | $579.9m | $1.1b | $1.8b | $1.7b | $2.1b | $2.5b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.